Poolbeg Pharma has in-licensed a late preclinical-stage, potentially broad-spectrum treatment for respiratory virus infections, representing the second expansion of its R&D pipeline in as many months. The new agent is a nasally-administered RNA-based approach with prophylactic and therapeutic a
